494 related articles for article (PubMed ID: 32743759)
21. Potential Impacts of
Lee KL; Lai TC; Wang YC; Shih PC; Yang YC; Tsao TC; Liu TC; Wen YC; Chang LC; Yang SF; Chien MH
Genes (Basel); 2021 Mar; 12(3):. PubMed ID: 33802737
[TBL] [Abstract][Full Text] [Related]
22. Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma.
Sun H; Liu SY; Zhou JY; Xu JT; Zhang HK; Yan HH; Huan JJ; Dai PP; Xu CR; Su J; Guan YF; Yi X; Yu RS; Zhong WZ; Wu YL
EBioMedicine; 2020 Oct; 60():102990. PubMed ID: 32927274
[TBL] [Abstract][Full Text] [Related]
23. Risk stratification for lung adenocarcinoma on EGFR and TP53 mutation status, chemotherapy, and PD-L1 immunotherapy.
Wu CH; Hwang MJ
Cancer Med; 2019 Oct; 8(13):5850-5861. PubMed ID: 31407494
[TBL] [Abstract][Full Text] [Related]
24. Impact of TP53 Mutations on EGFR-Tyrosine Kinase Inhibitor Efficacy and Potential Treatment Strategy.
Fu J; Tong Y; Xu Z; Li Y; Zhao Y; Wang T; Li C; Cang S
Clin Lung Cancer; 2023 Jan; 24(1):29-39. PubMed ID: 36117108
[TBL] [Abstract][Full Text] [Related]
25.
Biton J; Mansuet-Lupo A; Pécuchet N; Alifano M; Ouakrim H; Arrondeau J; Boudou-Rouquette P; Goldwasser F; Leroy K; Goc J; Wislez M; Germain C; Laurent-Puig P; Dieu-Nosjean MC; Cremer I; Herbst R; Blons H; Damotte D
Clin Cancer Res; 2018 Nov; 24(22):5710-5723. PubMed ID: 29764856
[No Abstract] [Full Text] [Related]
26. High Expression of
Deng H; Huang Y; Wang L; Chen M
Biomed Res Int; 2020; 2020():2071593. PubMed ID: 33134373
[TBL] [Abstract][Full Text] [Related]
27. [Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].
Zhu G; Li Y; Shi R; Xu S; Zhang Z; Cao P; Chen C; Liu H; Chen J
Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):236-244. PubMed ID: 33910272
[TBL] [Abstract][Full Text] [Related]
28. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
[TBL] [Abstract][Full Text] [Related]
29. EGFR-mutant lung adenocarcinoma harboring co-mutational tumor suppressor genes predicts poor prognosis.
Zhao Y; Pan Y; Cheng C; Zheng D; Zhang Y; Gao Z; Fu F; Li H; Zheng S; Zhuge L; Mao H; Kuang M; Tao X; Peng Y; Hu H; Xiang J; Li Y; Sun Y; Chen H
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1781-1789. PubMed ID: 32361787
[TBL] [Abstract][Full Text] [Related]
30. The clinicopathological and molecular characteristics of resected EGFR-mutant lung adenocarcinoma.
Zhou W; Liu Z; Wang Y; Zhang Y; Qian F; Lu J; Wang H; Gu P; Hu M; Chen Y; Yang Z; Zhao R; Lou Y; Han B; Zhang W
Cancer Med; 2022 Mar; 11(5):1299-1309. PubMed ID: 35023616
[TBL] [Abstract][Full Text] [Related]
31. Concordance of Abundance for Mutational
Wang Y; Liu H; Yu N; Xiang X
Curr Oncol; 2023 Sep; 30(9):8464-8476. PubMed ID: 37754531
[TBL] [Abstract][Full Text] [Related]
32. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
VanderLaan PA; Rangachari D; Mockus SM; Spotlow V; Reddi HV; Malcolm J; Huberman MS; Joseph LJ; Kobayashi SS; Costa DB
Lung Cancer; 2017 Apr; 106():17-21. PubMed ID: 28285689
[TBL] [Abstract][Full Text] [Related]
33. Genome-wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis.
Bjaanæs MM; Fleischer T; Halvorsen AR; Daunay A; Busato F; Solberg S; Jørgensen L; Kure E; Edvardsen H; Børresen-Dale AL; Brustugun OT; Tost J; Kristensen V; Helland Å
Mol Oncol; 2016 Feb; 10(2):330-43. PubMed ID: 26601720
[TBL] [Abstract][Full Text] [Related]
34. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
[TBL] [Abstract][Full Text] [Related]
35. Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations.
Ruiz-Cordero R; Ma J; Khanna A; Lyons G; Rinsurongkawong W; Bassett R; Guo M; Routbort MJ; Zhang J; Skoulidis F; Heymach J; Roarty EB; Tang Z; Medeiros LJ; Patel KP; Luthra R; Roy-Chowdhuri S
BMC Cancer; 2020 Jan; 20(1):83. PubMed ID: 32005111
[TBL] [Abstract][Full Text] [Related]
36. Significance of
Hou Y; Tan S; Wang G
Genet Test Mol Biomarkers; 2021 May; 25(5):346-354. PubMed ID: 33956533
[No Abstract] [Full Text] [Related]
37. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
[TBL] [Abstract][Full Text] [Related]
38. Weighted gene coexpression network analysis identifies hub genes related to KRAS mutant lung adenocarcinoma.
Dai D; Shi R; Han S; Jin H; Wang X
Medicine (Baltimore); 2020 Aug; 99(32):e21478. PubMed ID: 32769881
[TBL] [Abstract][Full Text] [Related]
39. Decoding tumor mutation burden and driver mutations in early stage lung adenocarcinoma using CT-based radiomics signature.
Wang X; Kong C; Xu W; Yang S; Shi D; Zhang J; Du M; Wang S; Bai Y; Zhang T; Chen Z; Ma Z; Wang J; Dong G; Sun M; Yin R; Chen F
Thorac Cancer; 2019 Oct; 10(10):1904-1912. PubMed ID: 31414580
[TBL] [Abstract][Full Text] [Related]
40. Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with
Offin M; Rizvi H; Tenet M; Ni A; Sanchez-Vega F; Li BT; Drilon A; Kris MG; Rudin CM; Schultz N; Arcila ME; Ladanyi M; Riely GJ; Yu H; Hellmann MD
Clin Cancer Res; 2019 Feb; 25(3):1063-1069. PubMed ID: 30045933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
